|
PER2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.39410047342403E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22959994911065E-09 |
| Normal-vs-Stage2 |
9.04950003821625E-09 |
| Normal-vs-Stage3 |
5.2895465785241E-12 |
| Normal-vs-Stage4 |
1.41819889165617E-11 |
| Stage1-vs-Stage2 |
7.451200E-01 |
| Stage1-vs-Stage3 |
3.440400E-03 |
| Stage1-vs-Stage4 |
1.491890E-02 |
| Stage2-vs-Stage3 |
7.205900E-02 |
| Stage2-vs-Stage4 |
1.125020E-01 |
| Stage3-vs-Stage4 |
9.670600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.19319998326262E-10 |
| Normal-vs-AfricanAmerican |
1.968350E-04 |
| Normal-vs-Asian |
9.61299999602261E-08 |
| Caucasian-vs-AfricanAmerican |
2.648200E-01 |
| Caucasian-vs-Asian |
2.084400E-01 |
| AfricanAmerican-vs-Asian |
8.644800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.78840053877138E-10 |
| Normal-vs-Female |
3.77989972655257E-10 |
| Male-vs-Female |
5.565600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.63819999180015E-09 |
| Normal-vs-Age(41-60Yrs) |
1.94720017887562E-10 |
| Normal-vs-Age(61-80Yrs) |
2.82900369796835E-11 |
| Normal-vs-Age(81-100Yrs) |
2.640300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.371800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.917600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.067000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.159200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.267600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.793800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.43819999998129E-06 |
| Classical-VS-Follicular |
8.152000E-01 |
| Classical-VS-Other |
4.631800E-01 |
| Classical-VS-Normal |
1.96049998457681E-09 |
| Tall-VS-Follicular |
1.569160E-04 |
| Tall-VS-Other |
2.132600E-01 |
| Tall-VS-Normal |
1.70330416437992E-12 |
| Follicular-VS-Other |
4.811600E-01 |
| Follicular-VS-Normal |
2.2564000001779E-08 |
| Other-VS-Normal |
2.416000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.93060012421142E-10 |
| Normal-vs-N1 |
1.40730005426803E-09 |
| N0-vs-N1 |
9.338600E-01 |
|
|
